
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6279036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
2	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,144
3	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.7	2,319
4	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
5	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design, Heart Rhythm, 2012, 9, 632-696, 21. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial	0.7	1,541
6	Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of	1.7	1,497
7	Cardiology (ESC) and the E. Europace, 2012, 14, 528-606. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. Heart Rhythm, 2007, 4, 816-861.	0.7	1,258
8	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	1.3	1,167
9	Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation. JAMA - Journal of the American Medical Association, 2014, 311, 498.	7.4	1,114
10	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	27.0	1,071
11	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	1.7	908
12	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021, 42, 17-96. HRSJE HRAJECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:	2.2	830
13	Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS): in collaboration with the American College of Cardiology (ACC), American Heart	1.7	741
14	Association (AHA), and the Soci. Europace, 2007, 9, 335-379. Identification of a Genetic Locus for Familial Atrial Fibrillation. New England Journal of Medicine, 1997, 336, 905-911.	27.0	533
15	Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training. Circulation, 2011, 123, 13-22.	1.6	394
16	Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST). Circulation, 2012, 125, 23-30.	1.6	357
17	Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 2007, 28, 836-841.	2.2	351
18	Electrocardiographic Recognition of the Epicardial Origin of Ventricular Tachycardias. Circulation, 2004. 109. 1842-1847.	1.6	335

#	Article	IF	CITATIONS
19	The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology. European Heart Journal, 2014, 35, 665-672.	2.2	301
20	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 2012, 9, 1524-1576.	0.7	300
21	Long-lasting sport practice and lone atrial fibrillation. European Heart Journal, 2002, 23, 477-482.	2.2	293
22	Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace, 2008, 10, 618-623.	1.7	289
23	Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European Heart Journal, 2014, 35, 501-507.	2.2	285
24	Gender Differences in Clinical Manifestations of Brugada Syndrome. Journal of the American College of Cardiology, 2008, 52, 1567-1573.	2.8	265
25	Exercise and the heart: the good, the bad, and the ugly. European Heart Journal, 2015, 36, 1445-1453.	2.2	254
26	Atrial Fibrillation Promotion by Endurance Exercise. Journal of the American College of Cardiology, 2013, 62, 68-77.	2.8	252
27	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2017, 14, 1375-1379. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure:	0.7	251
28	implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	Article	IF	CITATIONS
37	Sport practice and the risk of lone atrial fibrillation: A case–control study. International Journal of Cardiology, 2006, 108, 332-337.	1.7	212
38	Scar Dechanneling. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 326-336.	4.8	200
39	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic optionsa report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2012, 14, 8-27.	1.7	193
40	Natural History of Brugada Syndrome:. Journal of Cardiovascular Electrophysiology, 2003, 14, 455-457.	1.7	192
41	Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 111-121.	4.8	189
42	Reversibility of Cardiac Abnormalities in Adolescents With Anorexia Nervosa After Weight Recovery. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 808-813.	0.5	181
43	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	1.8	181
44	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, 2018, 39, 2942-2955.	2.2	181
45	Three-Dimensional Architecture of Scar and Conducting Channels Based on High Resolution ce-CMR. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 528-537.	4.8	179
46	Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. European Heart Journal, 2015, 36, 2510-2519.	2.2	169
47	Integration of 3D Electroanatomic Maps and Magnetic Resonance Scar Characterization Into the Navigation System to Guide Ventricular Tachycardia Ablation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 674-683.	4.8	153
48	Cardiac magnetic resonance–aided scar dechanneling: Influence on acute and long-term outcomes. Heart Rhythm, 2017, 14, 1121-1128.	0.7	148
49	Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker. JACC: Clinical Electrophysiology, 2020, 6, 94-106.	3.2	144
50	Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. Journal of the American College of Cardiology, 1995, 25, 65-69.	2.8	143
51	Prognostic Value of Electrophysiologic Investigations in Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 1004-1007.	1.7	142
52	Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010, 12, 1084-1089.	1.7	138
53	Nonsurgical transthoracic epicardial radiofrequency ablation. Journal of the American College of Cardiology, 2003, 41, 2036-2043.	2.8	135
54	Left Atrial Posterior Wall Isolation Does Not Improve the Outcome of Circumferential Pulmonary Vein Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 35-40.	4.8	129

#	Article	IF	CITATIONS
55	CMR-Guided Approach to Localize and Ablate Gaps in Repeat AF Ablation Procedure. JACC: Cardiovascular Imaging, 2014, 7, 653-663.	5.3	129
56	Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 752-759.	1.7	127
57	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556.	1.7	125
58	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal, 2019, 40, 3013-3021.	2.2	125
59	A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. European Heart Journal, 2018, 39, 3999-4008.	2.2	123
60	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nature Reviews Cardiology, 2016, 13, 230-237.	13.7	122
61	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121
62	Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. Heart Rhythm, 2018, 15, 1363-1371.	0.7	116
63	Diagnosis, management, and outcomes of patients with syncope and bundle branch block. European Heart Journal, 2011, 32, 1535-1541.	2.2	115
64	Emerging risk factors and the dose–response relationship between physical activity and lone atrial fibrillation: a prospective case–control study. Europace, 2016, 18, 57-63.	1.7	115
65	Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. European Heart Journal, 2014, 35, 1316-1326.	2.2	114
66	Enhanced Detection Criteria in Implantable Defibrillators. Journal of Cardiovascular Electrophysiology, 1998, 9, 261-268.	1.7	112
67	R-wave peak time at DII: A new criterion for differentiating between wide complex QRS tachycardias. Heart Rhythm, 2010, 7, 922-926.	0.7	112
68	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. European Heart Journal, 2014, 35, 2352-2362.	2.2	111
69	Scar Characterization to Predict Life-Threatening Arrhythmic Events andÂSudden Cardiac Death in Patients With Cardiac Resynchronization Therapy. JACC: Cardiovascular Imaging, 2018, 11, 561-572.	5.3	111
70	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. European Heart Journal, 2021, 42, 4731-4739.	2.2	111
71	3D delayed-enhanced magnetic resonance sequences improve conducting channel delineation prior to ventricular tachycardia ablation. Europace, 2015, 17, 938-945.	1.7	110
72	Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace, 2010, 12, 30-36.	1.7	109

#	Article	IF	CITATIONS
73	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
74	Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. European Heart Journal, 2009, 30, 1880-1884.	2.2	104
75	Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. Journal of the American College of Cardiology, 2001, 37, 529-533.	2.8	103
76	Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. Europace, 2017, 19, 1272-1279.	1.7	103
77	Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace, 2011, 13, 920-934.	1.7	99
78	Neurohormonal, Structural, and Functional Recovery Pattern After Premature Ventricular Complex Ablation Is Independent of Structural Heart Disease Status in Patients With Depressed LeftÂVentricular Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 1195-1202.	2.8	99
79	MRI Assessment of Ablationâ€Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. Journal of Cardiovascular Electrophysiology, 2015, 26, 473-480.	1.7	96
80	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
81	A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm, 2008, 5, 1434-1440.	0.7	93
82	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983.	7.1	91
83	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	1.7	86
84	Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. Nature Reviews Cardiology, 2017, 14, 88-101.	13.7	86
85	Optimizing the Programation of Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Left Bundle Branch Block. American Journal of Cardiology, 2007, 100, 1002-1006.	1.6	84
86	Validity of the Polar V800 monitor for measuring heart rate variability in mountain running route conditions. European Journal of Applied Physiology, 2018, 118, 669-677.	2.5	84
87	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis, 2011, 106, 1012-1019	3.4	81
88	Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and) Tj ETQq0 0 0 rgBT /Ove	erlaich: 10 T	f 5600137 Td (
89	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78

Predisposing Factors and Prognostic Value of Sustained Monomorphic Ventricular Tachycardia in the Early Phase of Acute Myocardial Infarction. Journal of the American College of Cardiology, 1996, 28, 1670-1676. 2.8 90 77

#	Article	IF	CITATIONS
91	Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29.	1.7	73
92	Atrial fibrillation and atrial flutter in athletes. British Journal of Sports Medicine, 2012, 46, i37-i43.	6.7	72
93	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS), Europace, 2019, 21, 7-8.	1.7	72
94	Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace, 2012, 14, 1578-1586.	1.7	71
95	Left atrial deformation predicts success of first and second percutaneous atrial fibrillation ablation. Heart Rhythm, 2015, 12, 11-18.	0.7	70
96	Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. American Journal of Cardiology, 1991, 68, 897-900.	1.6	68
97	Mechanism of Decrease in Mitral Regurgitation After Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2009, 2, 444-450.	2.6	68
98	Infarct transmurality as a criterion for first-line endo-epicardial substrate–guided ventricular tachycardia ablation in ischemic cardiomyopathy. Heart Rhythm, 2016, 13, 85-95.	0.7	68
99	Accessory Pathway Localization by QRS Polarity in Children with Wolff-Parkinson-White Syndrome. Journal of Cardiovascular Electrophysiology, 2002, 13, 1222-1226.	1.7	65
100	Improvement of Reverse RemodelingÂUsing Electrocardiogram Fusion-Optimized Intervals in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2018, 4, 181-189.	3.2	64
101	Hypertrophic Cardiomyopathy: Role of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 1998, 31, 1081-1085.	2.8	63
102	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq0 0	0 rgBT /Ov	erlgck 10 Tf
103	Use of delayed-enhancement magnetic resonance imaging for fibrosis detection in the atria: a review. Europace, 2017, 19, euw053.	1.7	61
104	Outcomes after radiofrequency catheter ablation of atrial tachycardia. American Journal of Cardiology, 2001, 87, 886-890.	1.6	60
105	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. European Heart Journal, 2019, 40, 3793-3799c.	2.2	60
106	<scp>EAARN</scp> score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on preâ€implantation risk factors. European Journal of Heart Failure, 2014, 16, 802-809.	7.1	59
107	Fate of Left Atrial Function as Determined by Real-Time Three-Dimensional Echocardiography Study After Radiofrequency Catheter Ablation for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 1285-1290.	1.6	58
108	Fusionâ€Optimized Intervals (FOI): A New Method to Achieve the Narrowest QRS for Optimization of the AV and VV Intervals in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 283-292.	1.7	58

#	Article	IF	CITATIONS
109	Radiofrequency Catheter Ablation for Arrhythmic Storm in Patients with An Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 971-975.	1.2	57
110	Electrocardiographic Optimization of Interventricular Delay in Cardiac Resynchronization Therapy: A Simple Method to Optimize the Device. Journal of Cardiovascular Electrophysiology, 2007, 18, 1252-1257.	1.7	57
111	Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology, 2013, 168, 4093-4097.	1.7	57
112	Substrate modification or ventricular tachycardia induction, mapping, and ablation as the first step? A randomized study. Heart Rhythm, 2016, 13, 1589-1595.	0.7	57
113	Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study. European Heart Journal, 2016, 37, 473-483.	2.2	57
114	New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. Heart Rhythm, 2015, 12, 1717-1725.	0.7	56
115	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace, 2011, 13, 1517-1525.	1.7	55
116	Mechanical Abnormalities Detected WithÂConventional Echocardiography AreÂAssociated With Response and Midterm Survival in CRT. JACC: Cardiovascular Imaging, 2014, 7, 969-979.	5.3	55
117	Long-Term Effect of Cardiac Resynchronization Therapy on Functional Mitral Valve Regurgitation. American Journal of Cardiology, 2009, 104, 383-388.	1.6	54
118	Novel Computational Analysis of Left Atrial Anatomy Improves Prediction of Atrial Fibrillation Recurrence after Ablation. Frontiers in Physiology, 2017, 8, 68.	2.8	52
119	Accuracy of left atrial fibrosis detection with cardiac magnetic resonance: correlation of late gadolinium enhancement with endocardial voltage and conduction velocity. Europace, 2021, 23, 380-388.	1.7	52
120	The electrocardiographic, clinical, and electrophysiologic spectrum of idiopathic monomorphic ventricular tachycardia. American Heart Journal, 1992, 124, 746-753.	2.7	50
121	Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace, 2018, 20, 512-519.	1.7	49
122	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	1.7	48
123	Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory?. Europace, 2011, 13, 486-491.	1.7	48
124	Left Atrial Contractility is Preserved After Successful Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 374-379.	1.7	47
125	Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping. Europace, 2009, 11, 1675-1682.	1.7	47
126	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. PLoS ONE, 2013, 8, e55427.	2.5	47

#	Article	IF	CITATIONS
127	Preferential regional distribution of atrial fibrosis in posterior wall around left inferior pulmonary vein as identified by late gadolinium enhancement cardiac magnetic resonance in patients with atrial fibrillation. Europace, 2018, 20, 1959-1965.	1.7	47
128	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
129	Atrial Fibrillation Induced by Atrioventricular Nodal Reentrant Tachycardia. American Journal of Cardiology, 1997, 79, 681-682.	1.6	46
130	Left atrial geometry and outcome of atrial fibrillation ablation: results from the multicentre LAGO-AF study. European Heart Journal Cardiovascular Imaging, 2018, 19, 1002-1009.	1.2	45
131	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace, 2019, 21, 1459-1467.	1.7	45
132	Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. European Journal of Heart Failure, 2010, 12, 283-287.	7.1	44
133	Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Respiratory Research, 2014, 15, 54.	3.6	44
134	Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2014, 11, 747-754.	0.7	44
135	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	4.8	44
136	Left atrial size and function by three-dimensional echocardiography to predict arrhythmia recurrence after first and repeated ablation of atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2014, 15, 515-522.	1.2	43
137	Fragmented QRS as a predictor of arrhythmic events in patients with hypertrophic obstructive cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 159-165.	1.3	42
138	Atrial functional and geometrical remodeling in highly trained male athletes: for better or worse?. European Journal of Applied Physiology, 2014, 114, 1143-1152.	2.5	41
139	Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management. Expert Review of Cardiovascular Therapy, 2017, 15, 601-618.	1.5	41
140	Significance of Q-wave regression after transmural acute myocardial infarction. American Journal of Cardiology, 1988, 61, 739-742.	1.6	40
141	Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs the Circumferential Pulmonary Veins Ablation. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 21-25.	1.3	40
142	Characterization of focal right atrial appendage tachycardia. Europace, 2007, 10, 105-109.	1.7	40
143	Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm, 2015, 12, 2434-2442.	0.7	40
144	EHRA White Paper: knowledge gaps in arrhythmia management—status 2019. Europace, 2019, 21, 993-994.	1.7	40

#	Article	IF	CITATIONS
145	Optimization of the Interventricular Delay in Cardiac Resynchronization Therapy Using the QRS Width. American Journal of Cardiology, 2009, 104, 1407-1412.	1.6	39
146	Cardiovascular Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an Animal Model. Journal of the American Heart Association, 2017, 6, .	3.7	39
147	Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace, 2019, 21, 746-753.	1.7	39
148	Radiofrequency Ablation of Anteroseptal, Para-Hisian, and Mid-Septal Accessory Pathways Using a Simplified Femoral Approach. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 735-741.	1.2	38
149	Analysis of mRNA from human heart tissue and putative applications in forensic molecular pathology. Forensic Science International, 2010, 203, 99-105.	2.2	38
150	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 804-810.	1.7	38
151	Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm, 2017, 14, 1864-1870.	0.7	38
152	Elucidation of hidden slow conduction by double ventricular extrastimuli: a method for further arrhythmic substrate identification in ventricular tachycardia ablation procedures. Europace, 2018, 20, 337-346.	1.7	38
153	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	1.7	38
154	Predictors of clinical efficacy of â€~Ablate and Pace' therapy in patients with permanent atrial fibrillation. Heart, 2012, 98, 297-302.	2.9	37
155	Benefit of Left Atrial Roof Linear Ablation in Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study. Journal of the American Heart Association, 2014, 3, e000877.	3.7	37
156	Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace, 2016, 19, euw212.	1.7	37
157	Predictors of atrial mechanical sensing and atrioventricular synchrony with a leadless ventricular pacemaker: Results from the MARVEL 2 Study. Heart Rhythm, 2020, 17, 2037-2045.	0.7	36
158	Anodal Capture in Cardiac Resynchronization Therapy Implications for Device Programming. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 940-945.	1.2	34
159	Biventricular pacing in hypertrophic obstructive cardiomyopathy: A pilot study. Heart Rhythm, 2011, 8, 221-227.	0.7	34
160	Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 70, 1991-2002.	2.8	34
161	Arrhythmias and sport practice. Heart, 2010, 96, 398-405.	2.9	33
162	Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response?. European Journal of Heart Failure, 2012, 14, 635-641.	7.1	33

#	Article	IF	CITATIONS
163	Relation of Response to Cardiac Resynchronization Therapy to Left Ventricular Reverse Remodeling. American Journal of Cardiology, 2006, 97, 876-881.	1.6	32
164	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace, 2017, 19, 132-138.	1.7	32
165	Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. European Journal of Preventive Cardiology, 2019, 26, 764-775.	1.8	32
166	Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace, 2010, 12, 1136-1140.	1.7	31
167	Extensive atrial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance associated with advanced interatrial block electrocardiogram pattern. Europace, 2017, 19, 377-377.	1.7	31
168	Reproducibility and accuracy of late gadolinium enhancement cardiac magnetic resonance measurements for the detection of left atrial fibrosis in patients undergoing atrial fibrillation ablation procedures. Europace, 2019, 21, 724-731.	1.7	31
169	Impact of anti-tachycardia pacing on atrial fibrillation burden when added on top of preventive pacing algorithms: results of the prevention or termination (POT) trial. Europace, 2007, 10, 28-34.	1.7	30
170	Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy. Europace, 2009, 11, 338-342.	1.7	30
171	Differential atrial performance at rest and exercise in athletes: Potential trigger for developing atrial dysfunction?. Scandinavian Journal of Medicine and Science in Sports, 2016, 26, 1444-1454.	2.9	30
172	Preparticipation cardiovascular evaluation for athletic participants to prevents sudden death: author's reply. Europace, 2017, 19, 883-883.	1.7	30
173	Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 740-746.	1.7	30
174	Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm, 2021, 18, 1336-1343.	0.7	30
175	Inappropriate Tachycardia Detection by a Biventricular Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 123-124.	1.2	29
176	Low Exposure Radiation with Conventional Guided Radiofrequency Catheter Ablation in Pregnant Women. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1299-1302.	1.2	29
177	Usefulness of Ventricular Dyssynchrony Measured Using M-Mode Echocardiography to Predict Response to Resynchronization Therapy. American Journal of Cardiology, 2007, 100, 84-89.	1.6	29
178	Circumferential pulmonary vein ablation: Does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm, 2010, 7, 612-618.	0.7	29
179	Registro Español de Ablación con Catéter. XIVÂInforme Oficial de laÂSección deÂElectrofisiologÃa yÂArritmias de laÂSociedad Española deÂCardiologÃa (2014). Revista Espanola De Cardiologia, 2015, 68, 1127-1137.	1.2	29
180	Contact force threshold for permanent lesion formation in atrial fibrillation ablation: A cardiac magnetic resonance–based study to detect ablation gaps. Heart Rhythm, 2016, 13, 37-45.	0.7	29

#	Article	IF	CITATIONS
181	Severity of structural and functional right ventricular remodeling depends on training load in an experimental model of endurance exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H459-H468.	3.2	29
182	Mapping Data Predictors of a Left Ventricular Outflow Tract Origin of Idiopathic Ventricular Tachycardia With V ₃ Transition and Septal Earliest Activation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 484-491.	4.8	28
183	Evolución de la mejora en los resultados y las complicaciones de la ablación por catéter de la fibrilación auricular: aprendizaje, técnicas y metodologÃa. Revista Espanola De Cardiologia, 2012, 65, 131-138.	1.2	28
184	Delayed Gadolinium Enhancement Magnetic Resonance Imaging Detected Anatomic Gap Length in Wide Circumferential Pulmonary Vein Ablation Lesions Is Associated With Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006659.	4.8	28
185	Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace, 2020, 22, 598-606.	1.7	28
186	Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case–control echocardiographic study. Europace, 2007, 9, 294-298.	1.7	27
187	Effect of Repeated Radiofrequency Catheter Ablation on Left Atrial Function for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2011, 108, 1741-1746.	1.6	27
188	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 877-884.	7.1	27
189	CardioPulse Articles. European Heart Journal, 2015, 36, 255-264.	2.2	27
190	Radiofrequency Ablation of a Posteroseptal Atrioventricular Accessory Pathway in a Left-Sided Tricuspid Ring with Ebsteinlike Anomaly in a Patient with Congenitally Corrected Transposition of the Great Arteries. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 133-136.	1.2	26
191	Morphology discrimination criterion wavelet improves rhythm discrimination in single-chamber implantable cardioverter-defibrillators: Spanish Register of morphology discrimination criterion wavelet (REMEDIO). Europace, 2009, 11, 727-733.	1.7	26
192	Nuevas evidencias, nuevas controversias: análisis crÃŧico de la guÃa de práctica clÃnica sobre fibrilación auricular 2010 de la Sociedad Europea de CardiologAa. Revista Espanola De Cardiologia, 2012, 65, 7-13.	1.2	26
193	Impact of operator experience and training strategy on procedural outcomes with leadless pacing: Insights from the Micra Transcatheter Pacing Study. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 834-842.	1.2	26
194	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
195	Impact of earliest activation site location in the septal right ventricular outflow tract for identification of left vs right outflow tract origin of idiopathic ventricular arrhythmias. Heart Rhythm, 2015, 12, 726-734.	0.7	25
196	Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation. Europace, 2020, 22, 1480-1486.	1.7	25
197	Reduction in new cardiac electronic device implantations in Catalonia during COVID-19. Europace, 2021, 23, 456-463.	1.7	25
198	Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. Europace, 2022, 24, 1119-1126.	1.7	25

#	Article	IF	CITATIONS
199	Cardiac resynchronization therapy: predictive factors of unsuccessful left ventricular lead implant. European Heart Journal, 2007, 28, 450-456.	2.2	24
200	The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. American Heart Journal, 2008, 156, 445-451.	2.7	24
201	Diagnosisâ€ŧoâ€ablation time in atrial fibrillation: A modifiable factor relevant to clinical outcome. Journal of Cardiovascular Electrophysiology, 2019, 30, 1483-1490.	1.7	24
202	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
203	Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation. Journal of the American College of Cardiology, 1999, 34, 351-357.	2.8	23
204	Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace, 2007, 10, 9-14.	1.7	23
205	Reversal of spherical remodelling of the left atrium after pulmonary vein isolation: incidence and predictors. Europace, 2014, 16, 840-847.	1.7	23
206	Molecular disturbance underlies to arrhythmogenic cardiomyopathy induced by transgene content, age and exercise in a truncated PKP2 mouse model. Human Molecular Genetics, 2016, 25, 3676-3688.	2.9	23
207	Safety and Outcomes of Ventricular Tachycardia Substrate Ablation During Sinus Rhythm. JACC: Clinical Electrophysiology, 2020, 6, 1435-1448.	3.2	23
208	Rate adaptive pacing in an intracardiac pacemaker. Heart Rhythm, 2017, 14, 200-205.	0.7	21
209	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace, 2020, 22, 1337-1344.	1.7	21
210	Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator. European Heart Journal, 2002, 23, 901-907.	2.2	20
211	Complete atrioventricular block does not reduce longâ€ŧerm mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 1412-1418.	7.1	20
212	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace, 2019, 21, 636-644.	1.7	20
213	Very high pacing thresholds during longâ€ŧerm followâ€up predicted by a combination of implant pacing threshold and impedance in leadless transcatheter pacemakers. Journal of Cardiovascular Electrophysiology, 2020, 31, 868-874.	1.7	20
214	Ventricular tachycardia burden reduction after substrate ablation: Predictors of recurrence. Heart Rhythm, 2021, 18, 896-904.	0.7	20
215	Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. Europace, 2007, 9, 942-946.	1.7	19
216	Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. International Journal of Cardiology, 2016, 223, 458-464.	1.7	19

#	Article	IF	CITATIONS
217	Left ventricular dysfunction is related to the presence and extent of a septal flash in patients with right ventricular pacing. Europace, 2017, 19, euw020.	1.7	19
218	Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. Europace, 2008, 10, 955-960.	1.7	18
219	Diferencias de género en el manejo de los pacientes con fibrilación auricular: análisis de base poblacional en un área básica de salud. Revista Espanola De Cardiologia, 2011, 64, 233-236.	1.2	18
220	EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. Europace, 2015, 17, 1688-93.	1.7	18
221	Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a case–control study. Europace, 2020, 22, 1805-1811.	1.7	18
222	Septal flash predicts cardiac resynchronization therapy response in patients with permanent atrial fibrillation. Europace, 2014, 16, 1342-1349.	1.7	17
223	The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future. Journal of the American Heart Association, 2018, 7, e010777.	3.7	17
224	Verification of threshold for image intensity ratio analyses of late gadolinium enhancement magnetic resonance imaging of left atrial fibrosis in 1.5T scans. International Journal of Cardiovascular Imaging, 2020, 36, 513-520.	1.5	17
225	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. Heart, 2020, 106, 1919-1926.	2.9	17
226	Gain in real-world cardiac resynchronization therapy efficacy with SyncAV dynamic optimization: Heart failure hospitalizations and costs. Heart Rhythm, 2021, 18, 1577-1585.	0.7	17
227	Reexcitation mechanisms in epicardial tissue: Role of Ito density heterogeneities and INa inactivation kinetics. Journal of Theoretical Biology, 2009, 259, 850-859.	1.7	16
228	Plasma tissue inhibitor of matrix metalloproteinaseâ€1 (TIMPâ€1): an independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 2010, 12, 492-498.	7.1	16
229	Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation. Europace, 2011, 13, 132-133.	1.7	16
230	Displacement of the target ablation site and ventricles during premature ventricular contractions: Relevance for radiofrequency catheter ablation. Heart Rhythm, 2012, 9, 1050-1057.	0.7	16
231	An easy-to-use, operator-independent, clinical model to predict the left vs. right ventricular outflow tract origin of ventricular arrhythmias. Europace, 2015, 17, 1122-1128.	1.7	16
232	Genetic analysis, in silico prediction, and family segregation in long QT syndrome. European Journal of Human Genetics, 2015, 23, 79-85.	2.8	16
233	Influence of myocardial scar on the response to frequent premature ventricular complex ablation. Heart, 2019, 105, heartjnl-2018-313452.	2.9	16
234	Advanced interatrial block: A predictor of covert atrial fibrillation in embolic stroke of undetermined source. Journal of Electrocardiology, 2020, 58, 113-118.	0.9	16

#	Article	IF	CITATIONS
235	Orthodromic Pacemaker-Mediated Tachycardia in a Biventricular System Without an Atrial Electrode. Journal of Cardiovascular Electrophysiology, 2004, 15, 1100-1102.	1.7	15
236	Improving Safety of Epicardial Ventricular Tachycardia Ablation Using the Scar Dechanneling Technique and the Integration of Anatomy, Scar Components, and Coronary Arteries Into the Navigation System. Circulation, 2012, 125, e466-8.	1.6	15
237	Postprocedural LGE MR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1065-1072.	1.7	15
238	Electrocardiographic optimization techniques in resynchronization therapy. Europace, 2019, 21, 1286-1296.	1.7	15
239	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. American Heart Journal, 2020, 220, 213-223.	2.7	15
240	Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. Europace, 2020, 22, 1391-1400.	1.7	15
241	Cardiovascular magnetic resonance determinants of ventricular arrhythmic events after myocardial infarction. Europace, 2022, 24, 938-947.	1.7	15
242	Actualización detallada de las guÃas de la ESC para el manejo de la fibrilación auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	1.2	14
243	Transthoracic epicardial ablation of mitral isthmus for treatment of recurrent perimitral flutter. Heart Rhythm, 2014, 11, 26-33.	0.7	14
244	Cardiac Resynchronization Therapy. Heart Failure Clinics, 2017, 13, 233-240.	2.1	14
245	Optimizing the clinical use of implantable defibrillators in patients with Brugada syndrome. Country Review Ukraine, 2007, 9, 174-180.	0.8	13
246	Effect of Cardiac Resynchronization Therapy on Left Ventricular Diastolic Function: Implications for Clinical Outcome. Journal of Cardiac Failure, 2013, 19, 795-801.	1.7	13
247	Aortic remodelling induced by obstructive apneas is normalized with mesenchymal stem cells infusion. Scientific Reports, 2019, 9, 11443.	3.3	13
248	Electrical Interference from an Abdominal Muscle Stimulator Unit on an Implantable Cardioverter Defibrillator:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1292-1293.	1.2	12
249	Predictores de ausencia de mejorÃa clÃnica a medio plazo con la terapia de resincronización cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 306-312.	1.2	12
250	Pseudo–Atrial Fibrillation, Rare Manifestation of Multiple Anterograde Atrioventricular Nodal Pathways. American Journal of Cardiology, 2007, 100, 154-156.	1.6	12
251	Consens per a la prevenciÃ ³ de la mort sobtada cardÃaca en els esportistes. Apunts Medicine De L'Esport, 2013, 48, 35-41.	0.5	12
252	Myocardial motion and deformation patterns in an experimental swine model of acute LBBB/CRT and chronic infarct. International Journal of Cardiovascular Imaging, 2014, 30, 875-887.	1.5	12

#	Article	IF	CITATIONS
253	Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. Europace, 2016, 18, 232-237.	1.7	12
254	Differentiating hypertrophic cardiomyopathy from athlete's heart: An electrocardiographic and echocardiographic approach. Journal of Electrocardiology, 2016, 49, 539-544.	0.9	12
255	Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. Heart Rhythm, 2017, 14, 1476-1484.	0.7	12
256	Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design. Clinical Research in Cardiology, 2018, 107, 539-547.	3.3	12
257	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATEâ€AF study Clinical Cardiology, 2018, 41, 440-449.	1.8	12
258	Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm, 2019, 16, 1849-1854.	0.7	12
259	International expert consensus on a scientific approach to training novice cardiac resynchronization therapy implanters using performance quality metrics. International Journal of Cardiology, 2019, 289, 63-69.	1.7	12
260	A validation study of intraoperative performance metrics for training novice cardiac resynchronization therapy implanters. International Journal of Cardiology, 2020, 307, 48-54.	1.7	12
261	Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace, 2021, 23, 1437-1445.	1.7	12
262	Long-term outcomes of ventricular tachycardia substrate ablation incorporating hidden slow conduction analysis. Heart Rhythm, 2020, 17, 1696-1703.	0.7	12
263	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation, 2022, 145, 906-915.	1.6	12
264	Improved Outcomes and Complications of Atrial Fibrillation Catheter Ablation Over Time: Learning Curve, Techniques, and Methodology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 131-138.	0.6	11
265	Use of MRI to guide electrophysiology procedures. Heart, 2014, 100, 1975-1984.	2.9	11
266	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm, 2015, 12, 1192-1200.	0.7	11
267	Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction. Heart Rhythm, 2017, 14, 592-598.	0.7	11
268	Comentarios a la guÃa ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular. Revista Espanola De Cardiologia, 2017, 70, 2-8.	1.2	11
269	Cryoballoon vs. radiofrequency lesions as detected by late-enhancement cardiac magnetic resonance after ablation of paroxysmal atrial fibrillation: a case–control study. Europace, 2020, 22, 382-387.	1.7	11
270	Quantification of Left Ventricular Asynchrony Throughout the Whole Cardiac Cycle with a Computed Algorithm: Application for Optimizing Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2009, 20, 1130-1136.	1.7	10

#	Article	IF	CITATIONS
271	Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice. BMC Cardiovascular Disorders, 2012, 12, 42.	1.7	10
272	Noncompaction Cardiomyopathy is Associated With Mechanical Dyssynchrony: A Potential Underlying Mechanism for Favorable Response to Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2013, 19, 80-86.	1.7	10
273	Posterior Coronary Vein as the Substrate for an Epicardial Accessory Pathway. Indian Pacing and Electrophysiology Journal, 2013, 13, 142-147.	0.6	10
274	Exercise and the heart: unmasking Mr Hyde. Heart, 2014, 100, 999-1000.	2.9	10
275	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovascular Disorders, 2019, 19, 120.	1.7	10
276	ACE2 and ACE in acute and chronic rejection after human heart transplantation. International Journal of Cardiology, 2019, 275, 59-64.	1.7	10
277	In silico pace-mapping: prediction of left vs. right outflow tract origin in idiopathic ventricular arrhythmias with patient-specific electrophysiological simulations. Europace, 2020, 22, 1419-1430.	1.7	10
278	Arrhythmogenic substrate detection in chronic ischaemic patients undergoing ventricular tachycardia ablation using multidetector cardiac computed tomography: compared evaluation with cardiac magnetic resonance. Europace, 2021, 23, 82-90.	1.7	10
279	Predictores de ausencia de mejorÃa clÃnica a medio plazo con la terapia de resincronización cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 306-312.	1.2	10
280	Late gadolinium enhancementâ€MRI determines definite lesion formation most accurately at 3 months post ablation compared to later time points. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 72-82.	1.2	10
281	Short Head-Up Tilt Test Potentiated with Oral Nitroglycerine:. Comparison with a Conventional Test Using Isoproterenol. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1085-1088.	1.2	9
282	Sex Differences in the Treatment of Patients With Atrial Fibrillation: Population-Based Study in a Local Health District. Revista Espanola De Cardiologia (English Ed), 2011, 64, 233-236.	0.6	9
283	Comparison of Hemodynamic versus Dyssynchrony Assessment for Interventricular Delay Optimization with Echocardiography in Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 984-990.	1.2	9
284	La presión arterial ambulatoria nocturna se asocia al remodelado auricular y la activación neurohormonal en pacientes con fibrilación auricular idiopática. Revista Espanola De Cardiologia, 2013, 66, 458-463.	1.2	9
285	Optimized pacing mode for hypertrophic cardiomyopathy: Impact of ECG fusion during pacing. Heart Rhythm, 2015, 12, 909-916.	0.7	9
286	Exercise, sex and atrial fibrillation: arrhythmogenesis beyond Y-chromosome?. Heart, 2015, 101, 1607-1609.	2.9	9
287	Fast Quasi-Conformal Regional Flattening of the Left Atrium. IEEE Transactions on Visualization and Computer Graphics, 2020, 26, 2591-2602.	4.4	9
288	Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic and prognostic implications. Europace, 2021, 23, 1559-1567.	1.7	9

#	Article	IF	CITATIONS
289	Ablation Lesion Assessment with MRI. Arrhythmia and Electrophysiology Review, 2022, 11, e02.	2.4	9
290	Incidence, pathophysiology and prognosis of exercise-induced sustained ventricular tachycardia associated with healed myocardial infarction. American Journal of Cardiology, 1992, 70, 875-878.	1.6	8
291	Left ventricular function and visual phase analysis with equilibrium radionuclide angiography in patients with biventricular device. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 912-921.	6.4	8
292	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-Value for Understanding the Effect of Cardiac Resynchronization Therapy. Ultrasound in Medicine and Biology, 2012, 38, 2186-2197.	1.5	8
293	Nighttime Ambulatory Blood Pressure is Associated With Atrial Remodelling and Neurohormonal Activation in Patients With Idiopathic Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2013, 66, 458-463.	0.6	8
294	Analysis of the arrhythmogenic substrate in human heart failure. Cardiovascular Pathology, 2013, 22, 133-140.	1.6	8
295	First clinical evaluation of an atrial haemodynamic sensor lead for automatic optimization of cardiac resynchronization therapy. Europace, 2016, 18, 755-761.	1.7	8
296	Inâ€vivo compatibility between pacemakers and dental equipment. European Journal of Oral Sciences, 2018, 126, 307-315.	1.5	8
297	Novel concepts in atrial fibrillation ablation—breaking the tradeâ€off between efficacy and safety. Journal of Arrhythmia, 2021, 37, 904-911.	1.2	8
298	Noninvasive Evaluation of Radiofrequency Lesions in the Human Ventricular Myocardium by Contrast-Enhanced Cardiac Magnetic Resonance. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 208-211.	4.8	7
299	Long-term benefit of first-line peri-implantable cardioverter–defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients. Europace, 2016, 19, euw096.	1.7	7
300	Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study. International Journal of Cardiovascular Imaging, 2016, 32, 1179-1188.	1.5	7
301	Atrial fibrillation progression: How sick is the atrium?. Heart Rhythm, 2017, 14, 808-809.	0.7	7
302	Safety and usefulness of a second Micra transcatheter pacemaker implantation after battery depletion. Europace, 2019, 21, 885-885.	1.7	7
303	Premature ventricular complex site of origin and ablation outcomes in patients with prior myocardial infarction. Heart Rhythm, 2021, 18, 27-33.	0.7	7
304	Cardiac Motion Estimation from Intracardiac Electrical Mapping Data: Identifying a Septal Flash in Heart Failure. Lecture Notes in Computer Science, 2009, , 21-29.	1.3	7
305	Ablación por radiofrecuencia para el tratamiento de la fibrilación auricular focal a través de cartografÃa circunferencial y aislamiento segmentario de las venas pulmonares. Revista Espanola De Cardiologia, 2003, 56, 361-367.	1.2	7
306	Exercise and atrial fibrillation: how health turns harm, and how to turn it back. Minerva Cardioangiologica, 2019, 67, 411-424.	1.2	7

#	Article	IF	CITATIONS
307	Left Bundle Branch Block. Cardiac Electrophysiology Clinics, 2021, 13, 671-684.	1.7	7
308	Conduction system pacing vs. biventricular pacing in patients with ventricular dysfunction and AV block. PACE - Pacing and Clinical Electrophysiology, 2022, , .	1.2	7
309	Lone atrial fibrillation and sport practice. The no gain without pain history revisited again?. International Journal of Cardiology, 2007, 118, 414-415.	1.7	6
310	Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 19-27.	1.3	6
311	Analysis of temporal delay in myocardial deformation throughout the cardiac cycle: Utility for selecting candidates for cardiac resynchronization therapy. Heart Rhythm, 2010, 7, 1580-1586.	0.7	6
312	Arrhythmias in the athlete. Herzschrittmachertherapie Und Elektrophysiologie, 2012, 23, 76-81.	0.8	6
313	Doble respuesta ventricular: otra vÃa a la taquicardia supraventricular en fisiologÃa doble del nódulo. Revista Espanola De Cardiologia, 2013, 66, 145-146.	1.2	6
314	Integración de la imagen mecánica, estructural y eléctrica para entender la respuesta a la terapia de resincronización cardiaca. Revista Espanola De Cardiologia, 2014, 67, 813-821.	1.2	6
315	Programming Pacemakers to Reduce and Terminate Atrial Fibrillation. Current Cardiology Reports, 2019, 21, 127.	2.9	6
316	Late Potential Abolition in Ventricular Tachycardia Ablation. American Journal of Cardiology, 2022, 174, 53-60.	1.6	6
317	Inappropriate shocks or inappropriate programming? A review of Guidant'sTM reconfirmation algorithm. Europace, 2009, 11, 1120-1122.	1.7	5
318	Electrophysiology: it is time to simplify!. Europace, 2009, 11, 985-986.	1.7	5
319	Biventricular / Left Ventricular Pacing in Hypertrophic Obstructive Cardiomyopathy: An Overview. Indian Pacing and Electrophysiology Journal, 2012, 12, 114-123.	0.6	5
320	Quantification of local changes in myocardial motion by diffeomorphic registration via currents: Application to paced hypertrophic obstructive cardiomyopathy in 2D echocardiographic sequences. Medical Image Analysis, 2015, 19, 203-219.	11.6	5
321	Prediction of premature ventricular complex origin in left vs. right ventricular outflow tract: a novel anatomical imaging approach. Europace, 2019, 21, 147-153.	1.7	5
322	Behavior of AV synchrony pacing mode in a leadless pacemaker during variable AV conduction and arrhythmias. Journal of Cardiovascular Electrophysiology, 2021, 32, 1947-1957.	1.7	5
323	Accuracy of standard bipolar amplitude voltage thresholds to identify late potential channels in ventricular tachycardia ablation. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 15-25.	1.3	5
324	Local Repolarization Abnormalities Induced by Transcatheter Radiofrequency Ablation in Pigs. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 1952-1960.	1.2	4

#	Article	IF	CITATIONS
325	Consenso sobre la terapia de Resincronización CardÃaca. Revista Espanola De Cardiologia Suplementos, 2005, 5, 3B-11B.	0.2	4
326	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Europace, 2008, 11, 132-132.	1.7	4
327	Dual Ventricular Response: Another Road to Supraventricular Tachycardia in Dual Atrioventricular Nodal Physiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 145-146.	0.6	4
328	GuÃa de práctica clÃnica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca. Revista Espanola De Cardiologia, 2014, 67, 58.e1-58.e60.	1.2	4
329	Letter by Bisbal et al Regarding Article, "Repeat Left Atrial Catheter Ablation: Cardiac Magnetic Resonance Prediction of Endocardial Voltage and Gaps in Ablation Lesion Sets― Circulation: Arrhythmia and Electrophysiology, 2015, 8, 753-753.	4.8	4
330	What have we learned of ablation procedures for atrial fibrillation?. Journal of Internal Medicine, 2016, 279, 439-448.	6.0	4
331	Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP. Heart Rhythm O2, 2021, 2, 405-411.	1.7	4
332	Documento de consenso sobre el tratamiento de la fibrilación auricular en los servicios de urgencias hospitalarios. Revista Espanola De Cardiologia, 2003, 56, 801-816.	1.2	4
333	Wytyczne ESC dotyczÄce stymulacji serca i terapii resynchronizujÄcej w 2013 roku. Kardiologia Polska, 2013, 71, 133-192.	0.6	4
334	Septal flash correction with Hisâ€Purkinje pacing predicts echocardiographic response in resynchronization therapy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 374-383.	1.2	4
335	Comparison of effectiveness of implantable cardioverter defibrillator in patients with idiopathic dilated cardiomyopathy versus those with proved coronary heart disease. American Journal of Cardiology, 2003, 92, 1227-1230.	1.6	3
336	Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thrombosis Research, 2006, 117, 235-240.	1.7	3
337	Epicardial ablation of syncopal ventricular tachycardia. Utility of the electrocardiogram. Europace, 2006, 8, 338-340.	1.7	3
338	Impact of Implementing Common Guidelines at Different Care Levels in a Healthcare Area on the Improvement of Atrial Fibrillation Treatment. Revista Espanola De Cardiologia (English Ed), 2007, 60, 392-403.	0.6	3
339	Usefulness of Echo-Guided Cardiac Resynchronization Pacing in Patients Undergoing "Ablate and Pace―Therapy for Permanent Atrial Fibrillation and Effects of Heart Rate Regularization and Left Ventricular Resynchronizationâ€â€A list of participating institutions and investigators appears in the Appendix American Journal of Cardiology, 2008, 102, 854-860.	1.6	3
340	Letter by Mont et al Regarding Article, "Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study― Circulation, 2009, 119, e195; author reply e196.	1.6	3
341	Innovations in Heart Rhythm Disturbances: Cardiac Electrophysiology, Arrhythmias, and Cardiac Pacing. Revista Espanola De Cardiologia (English Ed), 2013, 66, 116-123.	0.6	3
342	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Journal of Arrhythmia, 2014, 30, 327-349.	1.2	3

#	Article	IF	CITATIONS
343	Correlation between functional electrical gaps identified by ultrahigh-density mapping and by late gadolinium enhancement cardiac magnetic resonance in repeat atrial fibrillation procedure. HeartRhythm Case Reports, 2017, 3, 282-285.	0.4	3
344	Endurance training in young athletes: What happens in childhood, stays in childhood?. European Journal of Preventive Cardiology, 2019, 26, 1998-2000.	1.8	3
345	Left Bundle Branch Pacing. JACC: Case Reports, 2020, 2, 2225-2229.	0.6	3
346	Impact of cryoballoon applications on lesion gaps detected by magnetic resonance after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2020, 31, 638-646.	1.7	3
347	The imperative of consistency and proficiency in cardiac devices implant skills training. Open Heart, 2021, 8, e001629.	2.3	3
348	Anorexia nerviosa: una enfermedad con repercusiones cardÃacas potencialmente letales. Revista Espanola De Cardiologia, 2003, 56, 652-653.	1.2	3
349	Mechanisms of Sudden Cardiac Death. Drugs, 1991, 41, 16-23.	10.9	2
350	Coronary denervation attenuates coronary constriction induced by muscarinic receptor stimulation in pigs. Cardiovascular Research, 1996, 32, 311-319.	3.8	2
351	Endurance athletes: exploring the limits andbeyond. European Heart Journal, 2003, 24, 1469-1470.	2.2	2
352	Incidence of syncope after ICD implantation: low or high?. European Heart Journal, 2006, 27, 2481-2482.	2.2	2
353	Corrigendum to "Sport practice and the risk of lone atrial fibrillation: A case–control study― [International Journal of Cardiology 108/3 (2006) 332–337]. International Journal of Cardiology, 2007, 123, 74.	1.7	2
354	Estimulación en la insuficiencia cardiaca congestiva. Situación actual y perspectivas. Revista Espanola De Cardiologia Suplementos, 2007, 7, 102G-125G.	0.2	2
355	Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!. American Journal of Cardiology, 2009, 103, 894.	1.6	2
356	Skeletal myoblast implants induce minor propagation delays, but do not promote arrhythmias in the normal swine heart. Europace, 2010, 12, 1637-1644.	1.7	2
357	Bifocal Right Ventricular Resynchronization for the Failing Right Ventricle. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e78-81.	1.2	2
358	Assessing reverse remodeling in heart failure patients treated with cardiac resynchronization therapy and its impact on prognosis. Expert Review of Cardiovascular Therapy, 2012, 10, 1437-1448.	1.5	2
359	Complete atrioventricular block <i>does</i> reduce mortality in patients with atrial fibrillation treated with cardiac resynchronization therapy: reply. European Journal of Heart Failure, 2014, 16, 115-115.	7.1	2
360	Integration of Mechanical, Structural and Electrical Imaging to Understand Response to Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 813-821.	0.6	2

#	Article	IF	CITATIONS
361	Left Atrial Tachycardia After Atrial Fibrillation Ablation: Can Magnetic Resonance Imaging Assist the Ablation?. Canadian Journal of Cardiology, 2015, 31, 104.e1-104.e3.	1.7	2
362	Atrial fibrillation ablation: less is more?: FigureÂ1. European Heart Journal, 2015, 36, 1792-1793.	2.2	2
363	Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 789-796.	1.7	2
364	Presyncopal episodes after implantation of dual-chamber pacemaker programmed in SafeR pacing mode. Europace, 2017, 19, 807-807.	1.7	2
365	Cardiac magnetic resonance based ablation procedures: ready for take-off?. Europace, 2019, 21, 5-6.	1.7	2
366	Frequent premature ventricular complexes and normal ejection fraction: to treat or not to treat?. Heart, 2019, 105, 1386-1387.	2.9	2
367	LGE-MRI Characterization of Left Atrial Fibrosis: a Tool to Establish Prognosis and Guide Atrial Fibrillation Ablation. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	2
368	T-wave inversion in young athletes: Should we check their bones or their identity card? The quest for precision medicine. European Journal of Preventive Cardiology, 2019, 26, 638-640.	1.8	2
369	Inappropriate Shock Due to Air Entrapment in the Pocket of a Subcutaneous Implantable Cardioverter-defibrillator. Revista Espanola De Cardiologia (English Ed), 2019, 72, 79-81.	0.6	2
370	Automatic Detection of Slow Conducting Channels during Substrate Ablation of Scar-Related Ventricular Arrhythmias. Journal of Interventional Cardiology, 2020, 2020, 1-13.	1.2	2
371	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace, 2021, 23, 65-72.	1.7	2
372	Optimized singleâ€point left ventricular pacing leads to improved resynchronization compared with multipoint pacing. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 519-527.	1.2	2
373	Cardiac Resynchronization Therapy Response Is Equalized in Men and Women byÂElectricalÂOptimization. JACC: Clinical Electrophysiology, 2021, 7, 1400-1409.	3.2	2
374	Endurance Sport Practice and Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 2, .	0.5	2
375	Pacemaker selection: time for a rethinking of complex pacing systems. European Heart Journal, 2005, 27, 1126-1127.	2.2	1
376	Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: Correlation with echocardiography. Heart Rhythm, 2005, 2, S289.	0.7	1
377	Single-, dual-, or triple-chamber defibrillators: The simpler the better?. Heart Rhythm, 2006, 3, 1404-1405.	0.7	1
378	Corrigendum to 'Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals'. Europace, 2008, 10, 388-388.	1.7	1

#	Article	IF	CITATIONS
379	Pitfalls of Programming Sensing Polarities Using the Coronary Sinus Lead in Biventricular Pacemakers. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e22-5.	1.2	1
380	New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 7-13.	0.6	1
381	'Fight for sinus rhythm, or surrender?' European Heart Journal, 2014, 35, 1427-1429.	2.2	1
382	Deep breathing-triggered atrial fibrillation: An unusual mechanism terminated by focal RF ablation. Indian Pacing and Electrophysiology Journal, 2015, 15, 199-201.	0.6	1
383	Extraction of Sterile Leads Is the Preferred Approach Rather than Implanting a New Lead. Cardiac Electrophysiology Clinics, 2015, 7, 427-431.	1.7	1
384	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. Medicina ClÄnica (English Edition), 2016, 146, 423-428.	0.2	1
385	Thoracoscopic maze: yes, we can, but should we?. Europace, 2019, 21, 838-839.	1.7	1
386	Failure-free survival of the Riata implantable cardioverter-defibrillator lead after a very long-term follow-up. Indian Pacing and Electrophysiology Journal, 2019, 19, 140-144.	0.6	1
387	Determining the best approach to reduce the impact of exercise-induced atrial fibrillation: prevention, screening, or symptom-based treatment?. Expert Review of Cardiovascular Therapy, 2019, 17, 19-29.	1.5	1
388	The plus and pure left bundle branch pacing. Europace, 2021, 23, 1325-1325.	1.7	1
389	A programme for early diagnosis of atrial fibrillation: a multi-centre study in primary care. Family Practice, 2022, 39, 99-105.	1.9	1
390	Manifold Learning Characterization of Abnormal Myocardial Motion Patterns: Application to CRT-Induced Changes. Lecture Notes in Computer Science, 2013, , 450-457.	1.3	1
391	Endurance Exercise and Atrial Fibrillation. , 2020, , 659-681.		1
392	Improved procedural workflow for catheter ablation of paroxysmal AF with highâ€density mapping system and advanced technology: Rationale and study design of a multicenter international study. Clinical Cardiology, 2022, , .	1.8	1
393	An implantable defibrillator and what else?. European Heart Journal, 2009, 30, 1551-1553.	2.2	0
394	Cardiac resynchronization for New York Heart Association class IV patients: reply. Europace, 2010, 12, 1797-1798.	1.7	0
395	Reply to the Editor—Biventricular pacing in hypertrophic obstructive cardiomyopathy. Heart Rhythm, 2011, 8, e26.	0.7	0
396	Response to Letters Regarding Article, "Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training― Circulation, 2011, 124, .	1.6	0

#	Article	IF	CITATIONS
397	Remodelado auricular adverso en atletas de alto rendimiento: Estudio de deformación auricular con speckle tracking 2D. Revista Chilena De CardiologÃa, 2012, 31, 176-183.	0.0	Ο
398	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 472-472.	0.8	0
399	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 475-475.	0.8	0
400	EHRA is all of us. Herzschrittmachertherapie Und Elektrophysiologie, 2013, 24, 60-62.	0.8	0
401	Diagnóstico diferencial entre doble respuesta ventricular y extrasistolia hisiana bigeminada. Respuesta. Revista Espanola De Cardiologia, 2013, 66, 515-516.	1.2	Ο
402	Differential Diagnosis Between Dual Ventricular Response and Bigeminy Arising From the Bundle of His. Response. Revista Espanola De Cardiologia (English Ed), 2013, 66, 515-516.	0.6	0
403	Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology, 2015, 11, 565-583.	1.2	Ο
404	Respuesta. Medicina ClÃnica, 2017, 148, 96.	0.6	0
405	Selección de lo mejor del año 2016 en estimulación cardiaca: estimulación sinÂcables. Revista Espanola De Cardiologia, 2017, 70, 62-63.	1.2	Ο
406	Response to the letter to the editor on "Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation― Journal of Cardiovascular Electrophysiology, 2018, 29, E15.	1.7	0
407	Selection of the Best of 2017 in Catheter Ablation. Revista Espanola De Cardiologia (English Ed), 2018, 71, 303-304.	0.6	Ο
408	Atrial Fibrillation in Athletes. , 2018, , 241-256.		0
409	Mini-electrodes help identifying hidden slow conduction during ventricular tachycardia substrate ablation. Journal of Electrocardiology, 2018, 51, 1011-1013.	0.9	Ο
410	VT ablation and survival: A solved question?. International Journal of Cardiology, 2018, 267, 118-119.	1.7	0
411	Undetected displacement of a subcutaneous implantable cardioverter-defibrillator lead. importance of performing a chest X-ray during the first weeks post-implant: a case report. European Heart Journal - Case Reports, 2019, 3, 1-5.	0.6	Ο
412	Permanent phrenic paralysis after cryoablation of atrial fibrillation. Europace, 2020, 22, 337-337.	1.7	0
413	How to best assess ablation lesion formation with late gadolinium enhancement MRI. Journal of Cardiovascular Electrophysiology, 2020, 31, 3067-3068.	1.7	0
414	Atrial fibrillation drivers mapping: should I burn or should I go?. Europace, 2020, 22, 843-844.	1.7	0

#	Article	IF	CITATIONS
415	Epicardial ablation of ventricular tachycardia via the aortic cusps in ischemic cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2020, 73, 685-687.	0.6	0
416	Subcutaneous implantable cardioverter-defibrillator infection affecting deep tissues: is it always mandatory to remove the device?. Europace, 2020, 22, 776-776.	1.7	0
417	A Novel Biomarker Model for Detecting Patients With Atrial Fibrillation: A Development and Validation Study. SSRN Electronic Journal, 0, , .	0.4	0
418	Is cardiac magnetic resonance imaging a game changer in re-ablation of atrial fibrillation?—Authors' reply. Europace, 2021, 23, 1508-1509.	1.7	0
419	Prediction of stroke risk based on left atrial appendage morphology: from pareidolia to artificial intelligence. International Journal of Cardiovascular Imaging, 2021, 37, 2529-2531.	1.5	0
420	Nonâ€invasive isthmus identification of complex arrhythmias in congenital heart disease. Journal of Arrhythmia, 2021, 37, 1562-1566.	1.2	0
421	ls multipoint pacing superior to optimized singleâ€point pacing?. Journal of Cardiovascular Electrophysiology, 2021, 32, 3279-3279.	1.7	0
422	Endurance Sport Practice and Arrhythmias. , 2010, , 57-72.		0
423	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-value for the Understanding of CRT Outcome?. Lecture Notes in Computer Science, 2010, , 65-74.	1.3	0
424	Standardised Framework to Study the Influence of Left Atrial RF Catheter Ablation Parameters on Permanent Lesion Formation. Lecture Notes in Computer Science, 2017, , 96-105.	1.3	0
425	From Diagnosis of Cardiac Device Infection to Complete Extraction of the System. , 2020, , 95-108.		0
426	Endurance Sport Practice and Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 288.	0.5	0
427	Developments in imaging tools for AF. , 0, , .		0